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ABSTRACT
Purpose: Conjunctival melanoma (CM) is a rare but lethal form of cancer. Similar 
to cutaneous melanoma, CM frequently carries activating mutations in BRAF and 
NRAS. We studied whether CM as well as conjunctival benign and premalignant 
melanocytic lesions express targets in the mitogen-activated protein kinase (MAPK) 
and AKT pathways, and whether specific inhibitors can suppress CM growth in vitro.
Methods: 131 conjunctival lesions obtained from 129 patients were collected. The 
presence of BRAF V600E mutation and expression of phosphorylated (p)-ERK and p-AKT 
were assessed by immunohistochemistry. We studied cell proliferation, phosphorylation, 
cell cycling and apoptosis in three CM cell lines using two BRAF inhibitors (Vemurafenib 
and Dabrafenib), a MEK inhibitor (MEK162) and an AKT inhibitor (MK2206).
Results: The BRAF V600E mutation was present in 19% of nevi and 26% of 
melanomas, but not in primary acquired melanosis (PAM). Nuclear and cytoplasmic 
p-ERK and p-AKT were expressed in all conjunctival lesions. Both BRAF inhibitors 
suppressed growth of both BRAF mutant CM cell lines, but only one induced cell death. 
MEK162 and MK2206 inhibited proliferation of CM cells in a dose-dependent manner, 
and the combination of these two drugs led to synergistic growth inhibition and cell 
death in all CM cell lines.
Conclusion: ERK and AKT are constitutively activated in conjunctival nevi, PAM 
and melanoma. While BRAF inhibitors prohibited cell growth, they were not always 
cytotoxic. Combining MEK and AKT inhibitors led to more growth inhibition and cell 
death in CM cells. The combination may benefit patients suffering from metastatic 
conjunctival melanoma.
INTRODUCTION
Conjunctival melanoma (CM) is a rare malignant 
ocular surface tumor, arising from melanocytes in the 
conjunctiva. Although CM accounts for 5% of all ocular 
melanoma, over the past decades, an increase in occurrence 
has been reported from Finland [1], Sweden [2] and the 
United States [3]. CM has a high local recurrence rate after 
treatment [4, 5]. Surgical excision combined with adjuvant 
cryotherapy, brachytherapy, and/or topical chemotherapy 
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helps to prevent local recurrences of primary CM [5, 6]. 
A melanoma-related death rate of up to 29% at 10 years 
has been reported [5, 7]. However, the current therapeutic 
strategies are limited with regard to metastases.
Most CM originate in primary acquired melanosis 
(PAM) with atypia, while a small proportion arises 
from a preexisting nevus or de novo [8, 9]. The term 
“PAM”, created by Zimmerman [10], is used to describe 
the appearance of conjunctival pigmentation at some 
time after birth. PAM occurs with or without atypia: 
PAM without atypia consists of an increased amount of 
melanin pigment in the basal layer of the epithelium and/
or melanocytic hyperplasia [11], and generally does not 
develop into melanoma. In contrast, PAM with atypia 
contains atypical melanocytic hyperplasia that can 
extend into the more superficial non-basal portion of the 
epithelium and/or contains epithelioid melanocytes [12]. 
Up to 71% of CM has been reported to arise from PAM 
with atypia, while only up to 17% of CM is associated 
with conjunctival nevi [5, 13].
CM shares more similarities with cutaneous 
melanoma than with intraocular uveal melanoma. Like 
cutaneous melanoma, CM frequently harbors a BRAF 
mutation [14–16], as opposed to GNAQ/GNA11 mutations 
which are found in most cases of uveal melanoma. In a 
recent study, a BRAF V600E mutation was found in 29% of 
CM, and an NRAS mutation in 18% [17]. C-KIT mutations 
are seldom found in CM [18–20]. Mutant BRAF and NRAS 
are both known to activate the downstream kinases MEK1/2 
and ERK1/2, thereby promoting tumor proliferation [21]. 
BRAF inhibitors (BRAFi), including Vemurafenib and 
Dabrafenib, can prolong survival of metastatic cutaneous 
melanoma patients [22, 23]. In CM, Vemurafenib has 
been used to target metastases and a primary melanoma 
with opposite outcomes: the metastatic tumor progressed 
after 2 months of treatment while the primary tumor was 
controlled for 16 months [24, 25]. MEK inhibitor (MEKi) 
treatment is being tested in phase II and III clinical trials 
of metastatic cutaneous melanoma. Recently, it was found 
that the PI3K/AKT signaling pathway plays a major role 
in the initiation, progression, invasion, and drug resistance 
of cutaneous melanoma [26, 27]. Overactivity of PI3K/
AKT pathway can be induced by loss of activity of PTEN 
or by activating mutations in oncogene NRAS. A number 
of clinical trials using PI3K or AKT inhibitors (AKTi) are 
ongoing in patients with BRAF wild type (WT), BRAFi-
resistant and NRAS-mutant cutaneous melanoma, colon 
cancer and ovarian carcinoma [28].
To determine whether the above-mentioned 
inhibitors are of use in CM, we tested the effect of 
several potentially useful drugs on three CM cell lines, 
each of which has either a BRAF or NRAS mutation. We 
furthermore evaluated the phosphorylation of ERK and 
AKT in a substantial series of conjunctival nevi, PAM 
without atypia, PAM with atypia and primary CM tissues.
RESULTS
Phosphorylation of ERK and AKT in 
conjunctival melanoma
We determined the presence of BRAF V600E 
mutation in 131 pigmented conjunctival lesions from 129 
patients and analyzed the expression of phosphorylated 
(p)-ERK and p-AKT by immunohistochemistry (Table 
1). We observed BRAF V600E mutation in 19% of nevi 
(n=51) and 26% of melanoma (n=42) (Figure 1G). No 
BRAF V600E mutation was seen in any case of PAM 
without atypia (n=20) or PAM with atypia (n=18). One of 
the BRAF mutated melanomas evolved from a background 
of PAM.
The presence of p-ERK and p-AKT was studied 
by immunohistochemistry. AKT activation is associated 
with phosphorylation of two residues: serine 473 (Ser473) 
and threonine 308 (Thr308) [29]. Using the antibody 
p-AKT Ser473, most p-AKT staining was observed in 
nuclei (Figure 1N), while the p-AKT Thr308 antibody 
gave both nuclear and cytoplasmic staining (Figure 1M). 
In all 4 groups (nevi, PAM with and without atypia, and 
melanoma), expression of nuclear and cytoplasmic p-ERK 
and p-AKT was observed. P-ERK cytoplasmic staining 
was seen more frequently in PAM with atypia than in nevi 
(P = 0.027) or CM (P = 0.046). Similarly, p-ERK nuclear 
expression was seen more often in PAM with atypia than 
in nevi (P = 0.004), PAM without atypia (P = 0.028) 
or CM (P = 0.014). In groups of nevi and CM, neither 
cytoplasmic nor nuclear expression was associated with 
the presence of a BRAF mutation.
Molecular effects of Vemurafenib, Dabrafenib, 
MEK162 and MK2206
Western blot analysis was performed to determine 
the baseline protein levels of BRAF, p-ERK, ERK, p-AKT 
and AKT in two BRAF-mutant CM cell lines CRMM1 
and CM2005.1 and the NRAS-mutant cell line CRMM2 
(Figure 2A). BRAF is expressed in all three cell lines, with 
the highest level observed in CRMM1.
To determine whether the responses to drugs are 
pathway specific, we treated different cell lines with 
BRAFi (Vemurafenib, Dabrafenib), MEKi (MEK162) or 
AKTi (MK2206) for 24 hours and analyzed the effects on 
p-ERK and p-AKT levels by western blotting (Table 3). 
In CRMM1 (Figure 2B), the lowest dose of Vemurafenib 
(0.4 μM) and Dabrafenib (0.005 μM) already inhibited 
p-ERK. In contrast, in CM2005.1 (Figure 2D), increasing 
dosages of Vemurafenib and Dabrafenib decreased p-ERK 
gradually, while total ERK levels were not suppressed. 
However, p-ERK expression was increased after BRAFi 
treatment of the BRAF WT CRMM2 cells (Figure 2C). 
This phenomenon is similar to what has been observed 
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in BRAF WT cutaneous melanoma cell lines [30]. The 
effects on p-ERK levels, combined with cell viability data, 
indicate that the MAPK pathway plays an important role 
in growth of CM cell lines. In CRMM1 and CM2005.1, 
p-AKT was slightly attenuated after BRAFi and MEKi 
treatment without influencing total AKT, which might 
be an indirect effect due to the growth inhibition caused 
by these drugs. In CRMM2, p-AKT was upregulated by 
BRAFi, but downregulated by MEKi. Low concentrations 
of MK2206 (CRMM1 0.5 μM, CRMM2 2μM and 
CM2005.1 4μM) reduced the level of p-AKT, but higher 
concentrations were needed to suppress cell growth 
(Figure 3). To investigate whether the AKT pathway was 
effectively inhibited by MK2206, we determined the 
p-PRAS40 level, since PRAS40 is a direct downstream 
target molecule of AKT. As shown in Figure 3E, levels 
of p-PRAS40 were strongly reduced in all three cell lines 
upon MK2206 treatment at relative low concentrations, 
indicating that AKT activity was decreased by MK2206; 
however, this inhibition was not sufficient to decrease the 
cell growth of CRMM2 and CM2005.1.
In vitro activity of BRAF, MEK and AKT 
inhibitors in CM cell lines
Cells were treated with each drug at 5 different 
concentrations and survival was determined 72 hours 
later (Figure 3). As shown in Figure 3, Vemurafenib 
Table 1: Frequency of positively-staining cells in an immunohistological analysis of BRAF V600E mutation, p-ERK 











P valuec (Nevi 
vs. CM)
BRAF V600E mutationa     
 Negative 30 (81) 17 (100) 13 (100) 29 (74) 0.48
 Positive  7 (19)  0 (0)  0 (0) 10 (26)  
P-ERK cytoplasmic expressionb     
 Absent 27 (75) 12 (75)  8 (44) 26 (72) 0.79
 Present  9 (25)  4 (25) 10 (56) 10 (28)  
P-ERK nuclear expressionb     
 Absent 29 (83) 13 (81)  8 (44) 28 (78) 0.59
 Present  6 (17)  3 (19) 10 (56)  8 (22)  
P-AKT Ser473 cytoplasmic expressionb    
 Absent 31 (82) 10 (83)  7 (78) 29 (74) 0.41
 Present  7 (18)  2 (17)  2 (22) 10 (26)  
P-AKT Ser473 nuclear expressionb    
 Absent  9 (24)  2 (17)  3 (33)  5 (13) 0.24
 Present 29 (76) 10 (83)  6 (67) 33 (87)  
P-AKT Thr308 cytoplasmic expressionb    
 Absent 12 (33) 10 (91)  8 (80) 14 (37) 0.75
 Present 24 (67)  1 (9)  2 (20) 24 (63)  
P-AKT Thr308 nuclear expressionb    
 Absent 22 (61)  5 (45)  7 (70) 26 (68) 0.51
 Present 14 (39)  6 (55)  3 (30) 12 (32)  
a BRAF V600E mutation was scored as positive or negative.
b The phosphorylated protein expression was evaluated according to IRS scoring system, 0-1 was regarded as absent, and 
2-12 was regarded as present.
c Pearson chi-square test was applied to compare nevi group versus CM group for indicated protein expression. All tests 
were two-sided, and P values of ≤0.05 were considered significant.
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and Dabrafenib inhibited the growth of the BRAF-
mutant cell lines CRMM1 and CM2005.1, but not of the 
NRAS-mutant cell line CRMM2. MEK162 and MK2206 
inhibited growth of all CM cell lines in a dose-dependent 
manner, although only high concentrations of MK2206 
were able to suppress the proliferation of CRMM2 and 
CM2005.1. Table 2 summarizes the IC50 values of each 
agent for the three CM cell lines. Although CRMM1 
and CM2005.1 both harbor the BRAF V600E mutation, 
their sensitivity to BRAFi differed very much. No 
Figure 1: HE staining, BRAF V600E expression and phosphorylation of ERK and AKT in CM. A-E. nevus, F-J. BRAF 
V600E mutated melanoma, K-O. BRAF V600E negative melanoma. HE staining (A, F, K). Positive staining for p-AKT Thr308, p-AKT 
Ser473 and p-ERK occurred in a cytoplasmic (H, I) and nuclear (C, M, N) fashion and in combination (D, E, J). Negative staining (B, L, 
O). Staining patterns for these proteins did not correlate with malignant progression. All images were taken at the magnification of ×400.
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indications for PTEN loss of function were found in the 
BRAF V600E mutated cell lines that could explain this 
difference. However, we did find a deletion in exon 2 of 
PTEN in the NRAS mutant cell line CRMM2.
G1 arrest and apoptosis after exposure to single 
drug treatment
To obtain more insight into the effects of kinase 
inhibitors on cell growth and survival, we investigated 
their impact on cell cycle profiles using flow cytometry 
Figure 2: Effect of BRAFi, MEKi and AKTi treatment on ERK and AKT phosphorylation of CM cells. A. Basal protein 
level of p-ERK, p-AKT and PARP signalling in untreated cell lines. B-D. Cropped western blots of CRMM1, CRMM2 and CM2005.1 
treated with increasing doses of Vemurafenib, Dabrafenib, MEK162 and MK2206 at 24 hrs, showing changes in p-ERK and p-AKT. E. To 
confirm the efficacy of MK2206 at the molecular level, the downstream substrate of AKT, p-PRAS40, was detected after 24 hrs of exposure 
to MK2206. All experiments were repeated three times, and representative graphs are shown.
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(Figure 4A-4C). Treatment with 4 different kinase 
inhibitors of cell line CRMM1 resulted in strong G1 
arrest. MEK162 and MK2206 increased the sub-G1 
fraction, indicating that these two drugs were able to 
induce cell death. As expected, BRAFi did not induce 
any cell cycle change in CRMM2. Both MEK162 and 
MK2206 treatment led to G1 arrest, a modest increase 
in the sub-G1 fraction and a reduced number of S-phase 
cells (Supplementary Figure S2), although the effect of 
MK2206 was not very strong. In CM2005.1, G1 arrest 
and depletion of S-phase cells were found after all drug 
treatments, although MK2206 treatment did not result in a 
reduced G2/M phase. Some increase in sub-G1 cells was 
detected upon all treatments, although it was very modest 
after MK2206 treatment.
Poly (ADP-ribose) polymerase (PARP) cleavage is 
often associated with apoptotic cell death and has served 
as a marker for apoptosis and caspase activity [31]. 
CRMM1 showed high baseline level of PARP (Figure 2A), 
while CRMM2 and CM2005.1 showed modest and low 
PARP expression, respectively. Figure 4D shows that at 
the indicated concentrations, Vemurafenib and Dabrafenib 
promoted PARP cleavage in CM2005.1, but not in 
CRMM1 and CRMM2. MEK162 induced some cleaved 
PARP in cell line CM2005.1, while PARP cleavage was 
weak in CRMM1 and CRMM2. MK2206 treatment led to 
low PARP cleavage in all cell lines.
Synergistic growth inhibition and cell cycle 
arrest by combining MEK162 with MK2206
Treatment of MEKi combined with AKTi has 
been used to treat BRAF-mutant, BRAF-WT and NRAS-
mutant cutaneous melanoma patients [28]. We tested 
whether combining a MEK and AKT inhibitor would be 
effective in CM cell lines. We treated CRMM1, CRMM2 
and CM2005.1 with varied concentrations of MEK162, 
MK2206 or the combination of MEK162 and MK2206 
for 72 hours, and evaluated cell growth. Synergy studies 
were performed using the method of Chou [32]. Figure 
5 shows that MEK162 and MK2206 were synergistic in 
all cell lines, with synergy confirmed by CI values. These 
results suggest that at low concentrations, the two drugs 
may be used clinically to inhibit cell growth effectively.
To investigate whether combination treatments 
would inhibit cell cycle progression and induce more 
cell death than single treatments, we performed flow 
cytometry. In all cell lines, the combination of MEK162 
Table 3: Summary of drugs effects on cell proliferation and protein expression in vitro
 CRMM1 CRMM2 CM2005.1
Mutations a    
 BRAF V600E + - +
 NRAS Q61L - + -
Inhibitiont of cell proliferation b   
 BRAFi    
  Vemurafenib + - +
  Dabrafenib + - +
 MEKi    
  MEK162 + + +
 AKTi    
  MK2206 + + +
Drug effect on phosphorylated protein expression c  
 Vemurafenib p-ERK↓ p-ERK↑ p-ERK↓
 Dabrafenib p-ERK↓ p-ERK↑ p-ERK↓
 MEK162 p-ERK↓ p-ERK↓ p-ERK↓
 MK2206 p-AKT↓ p-AKT↓ p-AKT↓
a “+” means mutant, and “-” indicates wild type.
b “+” shows cell proliferation was inhibited, while “-” demonstrates cell viability was not influenced.
c “↑” represents phosphorylation of proteins was increased, while “↓” implies phosphorylation of proteins was decreased.
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and MK2206 at low concentrations caused slightly 
stronger G1 arrest and depletion of S-phase compared 
to single treatments (Figure 6). The combination of high 
concentrations induced stronger sub-G1 fractions than 
single agents (Figure 7).
DISCUSSION
Uveal melanomas, in contrast to conjunctival 
melanomas, lack BRAF or NRAS mutations but frequently 
have mutations in GNAQ, GNA11, BAP1, SF3B1 or 
EIF1AX [33]. To date, the reports describing the impact 
of kinase pathways in conjunctival melanoma are limited. 
Our results show that MAPK and AKT-signaling pathways 
are activated in both benign, premalignant and malignant 
conjunctival melanocytic lesions. In our series, BRAF 
V600E mutations occur in 19% of nevi and 26% of CM, 
but not in PAM, which confirms previous results [16]. 
Likewise, BRAF V600E mutations have been described 
to be less frequent in lentigo maligna lesions of the skin 
which show a comparable lentiginous histopathology 
as PAM [34]. Furthermore, similar to the findings in 
melanocytic nevi and cutaneous melanoma [35, 36], we 
report that BRAF mutations do not determine the tumor’s 
ERK phosphorylation status. It is unlikely that technical 
problems such as tissue fixation and the high temperature 
used for antigen retrieval impaired the staining of 
p-ERK, because positive p-ERK cells were abundant in 
Figure 3: Cell viability assessed by In-cell western assay. A-C. CRMM1, CRMM2 and CM2005.1 were counted and seeded, and 
drugs were added one day later at indicated concentrations. Cell viability was measured after 72hrs. All experiments were repeated three 
times, and the representative data were expressed as mean ± standard error of the mean (SEM).
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Figure 4: BRAFi, MEKi and AKTi induce cell cycle alteration and apoptosis. A-C. Representative flow cytometry analysis 
72hrs post treatment as indicated. D. Cropped western blots of PARP cleavage in cell lines treated with inhibitors at 72hrs.
Table 2: The sensitivity of conjunctival melanoma cell lines to Vemurafenib, Dabrafenib, MEK162 and MK2206




MEK162 (μM) MK2206 (μM)
CRMM1 BRAF V600E 0.99±0.07 0.10±0.01 0.09±0.02 4.90±1.25
CRMM2 NRAS Q61L >6.4 >1.25 0.05±0.01 9.67±0.91
CM2005.1 BRAF V600E 0.10±0.01 0.003±0.001 0.03±0.01 16.4±1.61
Cells were exposed to the single agent for 72 hrs to assess the cell viability. And the dose-response IC50 values were 
calculated using Compusyn software. Data were presented as the mean ± SD from at least 3 independent experiments.
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Figure 5: Synergistic growth inhibition using the combination of MEK162 and MK2206. Mono or combination treatments 
were performed on CRMM1 A., CRMM2 B. and CM2005.1 C. using MEK162 and MK2206 with indicated concentrations. Cell 
proliferation was measured after 72hrs treatment, and the effects of drug as fraction of control cells were calculated. The combination index 
(CI), reflecting the extent of synergy or antagonism for two drugs, was obtained for each drug combination. CI<0.9, synergy; 0.9<CI<1.1, 
additive effect; CI>1.1, antagonism. The experiments were performed three times and representative data were expressed as mean ± SEM.
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positive control tissues (data not shown). Recently, loss 
of function mutations in NF1 have been described in a 
high percentage of cutaneous melanoma. NF1 suppression 
can lead to increased RAS activation in melanoma, 
which may explain the lack of correlation between ERK 
phosphorylation and BRAF mutational status [37, 38].
Although p-ERK and p-AKT are regarded as 
being predominantly situated in the cytoplasm, the 
Figure 6: Enhanced G1 arrest induced by MEK162 combined with MK2206 at low concentrations. Single or combination 
treatments were performed in CRMM1 A. and CRMM2 B. using 0.025μM MEK162 and 2μM MK2206 and in CM2005.1 C. using 
0.005μM MEK162 and 1μM MK2206. Flow cytometry was analyzed after 72hrs of treatment.
Oncotarget58031www.impactjournals.com/oncotarget
phosphorylation of ERK and AKT in the nucleus is 
essential for nuclear translocation and activation of 
transcription factors [39, 40]; we therefore scored the 
staining in nuclei as well as in the cytoplasm. Our data 
show that, in general, p-ERK and p-AKT are indeed 
expressed in both nuclei and cytoplasm among all 
diagnostic groups of conjunctival melanocytic lesions, 
although with variable percentages. These results indicate 
Figure 7: Increased sub-G1 fractions induced by MEK162 combined with MK2206 at high concentrations. Mono or 
combination treatments were performed in CRMM1 A. and CRMM2 B. using 1µM MEK162 and 10µM MK2206 and in CM2005.1 C. 
using 1μM MEK162 and 11μM MK2206. Flow cytometry was studied after 72hrs of treatment.
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that MAPK and PI3K/AKT pathways are both potential 
targets for pharmacologic therapies in CM.
To investigate the effect of different drugs on cell 
proliferation and cell death, we tested BRAF, MEK and 
AKT inhibitors on three CM cell lines. Vemurafenib and 
Dabrafenib are selective BRAF inhibitors, and have been 
approved by the FDA as single agents for treatment of 
metastatic cutaneous melanoma. MEK162 and MK2206 
target MEK and AKT respectively. Although CRMM1 
and CM2005.1 both harbor a BRAF V600E mutation, 
their sensitivity to BRAFi differed greatly: CRMM1 
required a much higher dose of Dabrafenib to inhibit 
cell growth compared to CM2005.1. This could not be 
explained by loss of function in PTEN. Additionally, we 
demonstrate that BRAFi induced apoptosis of CM2005.1 
cells. The cell cycle analysis indicates that BRAFi 
inhibited cell growth of CRMM1 by inducing a G1 
arrest. In contrast, Vemurafenib and Dabrafenib did not 
inhibit cell proliferation of CRMM2, and they led to an 
increased p-ERK expression. This finding is in agreement 
with other preclinical studies in other malignancies, in 
which selective BRAFi stimulated cell growth and ERK 
phosphorylation in BRAF WT and NRAS mutant cutaneous 
melanoma cell lines [41–43]. The mechanism of the 
detrimental effects is through paradoxical-activation of 
RAS and receptor tyrosine kinases, which subsequently 
cause MAPK pathway hyperactivation through CRAF 
[44].
MEK162 inhibits the downstream RAS/RAF 
pathway target MEK, thereby decreasing p-ERK levels 
and suppressing cell growth. We did not find other 
studies that have treated CM cells with this novel drug. 
Proliferation of all three cell lines was inhibited through 
downregulation of p-ERK upon MEK162 treatment. 
Furthermore, the data of cell cycle profiles and PARP 
cleavage show that in addition to cytostatic effects, 
MEK162 alone can prompt apoptosis, regardless of 
BRAF or NRAS mutations. Importantly, IC50 values for 
cell culture are much lower than known plasma levels 
of MEK162 in patients (0.6-1 μM). However, similar to 
BRAFi, the disadvantage is that constitutive activation of 
the MAPK pathway can frequently lead to cross-talk with 
other signal transduction pathways, enabling melanoma 
cells to escape from MEK inhibition [45]. Current MEKi 
have more clinical side effects than Vemurafenib and 
Dabrafenib.
The PI3K/AKT signal transduction pathway is 
considered a potential co-target for BRAF and NRAS mutant 
cutaneous melanoma [22]. To the best of our knowledge, 
we are the first to attempt AKT inhibition in CM in vitro. 
Our results show that MK2206 inhibited proliferation in all 
CM cell lines, but at variable doses, and independent of their 
effect on p-AKT and p-PRAS40, indicating that the growth 
inhibitory effect induced by MK2206 is not specific or at 
least partly caused by off-target effects.
With the clinical availability of PI3K, AKT and 
mTOR inhibitors, a number of trials are now ongoing in 
cutaneous melanoma. Our studies show that combining 
MEK162 with MK2206 has a synergistic inhibitory 
effect on proliferation of three CM cell lines, regardless 
of their sensitivity to the individual agents. Mutations 
in the G-α-proteins GNAQ and GNA11 that occur in 
91% of uveal melanoma also activate MAPK and PI3K/
AKT pathways, which implies that the combination of 
MEK and AKT inhibitors may also be profitable for this 
patient group. Future studies on cutaneous and uveal 
melanoma cell lines are therefore warranted to evaluate 
the efficacy of combination treatment of MEK and 
AKT inhibitors. In clinical treatment, one may argue 
that multi-signal pathway blockades generate more side 
effects than individual kinase inhibitor. On the other 
hand, we have shown that combined treatment could 
be effective at considerably lower drug dosages and 
potentially ameliorate detrimental side effects.
In summary, our data suggest that the ERK and AKT 
are constitutively activated in all conjunctival melanocytic 
lesions. Our in vitro study shows some growth inhibition 
and cytotoxic effect of kinase inhibitors and provides a 
rationale for the clinical application of these compounds in 
CM. Our results indicate that co-inhibition of the MAPK 
and AKT pathways may improve their efficacy. Clinical 
studies are now indicated to test the efficacy of MAPK and 
AKT inhibitors in metastatic CM.
MATERIALS AND METHODS
Patients and samples
Paraffin-embedded tissue specimens were 
retrieved from the archive of the Department of 
Pathology of the Erasmus University Medical Center 
from patients with a conjunctival melanocytic lesion 
diagnosed between 1987 and 2013. The Institutional 
Review Board of the Erasmus University Medical 
Center waived the need for approval because of the 
retrospective and non-interventional character of the 
study. The study adhered to the tenets of the Declaration 
of Helsinki. Two hundred and seventy-eight samples 
obtained from 131 conjunctival lesions of 129 patients 
contained enough material for the study. In our patient 
cohort, CM were derived from PAM (59.5%, n=25), 
de novo (28.6%, n=12) and nevi (11.9%, n=5). All 
melanomas described were invasive. The metastatic 
rate was 21.4% (n=9). Out of 18 PAM with atypia, 8 
had severe atypia and 10 moderate atypia. No cases with 
minor atypia were included. The diagnosis was reviewed 
and the original slides were assessed according to the 
AJCC criteria. Because of the high recurrence rate, some 
patients underwent multiple surgeries.
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Construction of tissue microarray (TMA) 
samples
Carefully selected cores of 1 mm in diameter 
were taken from paraffin-embedded conjunctival tumor 
samples and assembled in a grid pattern into seven 
tissue microarrays. Positive control samples consisted of 
brain, liver, tonsil, heart, lung, gut and skin. The 4-μm 
sections were cut from TMA and were stained with 
hematoxylin and eosin (HE), and anti-Melan A to confirm 
the presence of the expected tissue histology within 
each tissue core. Additional sections were cut for further 
immunohistochemical analysis.
Immunohistochemistry (IHC)
We assessed the expression of p-ERK, 
p-AKT Ser473, p-AKT Thr 308 and BRAF V600E. 
Immunohistochemistry was performed with an automated 
staining system (Ventana BenchMark ULTRA, Ventana 
Medical Systems Inc., Tucson, AZ, USA) using the 
alkaline-phosphatase method for all antibodies and a 
red chromogen. Briefly, following deparaffinization and 
heat-induced antigen retrieval for 60 minutes, the tissue 
sections were incubated with primary antibody anti-
MAP kinase diphosphorylated ERK 1/2 (1:1000; M8159, 
Sigma-Aldrich, St. Louis, MO, USA), p-AKT Ser473 
(sc-135651; 1:25, Santa Cruz Biotechnology; Dallas, 
TX, USA), p-AKT Thr 308 (sc-135650, 1:50, Santa Cruz 
Biotechnology), BRAF-V600E (26039, 1:50, NewEast 
Biosciences, Malvern, PA, USA) or Melan A (clone A103, 
Ventana) for 1 hour at 36°C. A subsequent amplification 
step was followed by incubation with hematoxylin II 
counter stain for 8 minutes and then bluing reagent for 
8 minutes according to the manufacturer’s instructions 
(Ventana). The immunostained TMAs were analyzed with 
light microscopy (Leica DM 300, Leica, Eindhoven, the 
Netherlands) by two different observers at different time 
points. The samples were scored using the immunoreactive 
scoring (IRS) method, described by Remmele and Stegner 
[46]. The IRS evaluates the staining intensity and the 
proportion of positive cells, which results in two scores: 
an intensity score (IS) and a proportion score (PS). The 
value of the IS varies from 0 to 3 points and the value of 
the PS varies from 0 to 4 points. Multiplying these scores 
yields the IRS (0 - 12 points). The representative pictures 
of staining were taken with an Olympus DP25 camera, and 
acquired by Olympus CellSens Entry 1.9 software. The 
immunohistochemical markers stained the cytoplasm of 
the melanocytes. Some markers also stained the nucleus. 
For these markers, the staining of the cytoplasm and 
nucleus were analyzed and scored separately.
Reagents
Vemurafenib (PLX4032, S1267), Dabrafenib 
(GSK2118436, S2807), MEK162 (ARRY-162, S7007) and 
MK2206 (S1078) were purchased from Selleck Chemicals 
(Huissen, The Netherlands). All drugs were dissolved in 
dimethyl sulfoxide (DMSO) to reach a stock concentration 
of 10 mM. For in vitro tests, the stock solution was diluted 
in the indicated fresh medium.
Cell lines and cell culture
CM cell lines CRMM1 and CRMM2 were 
established by G. Nareyeck, Essen, Germany [47], and 
kindly provided by M. Madigan, Sydney, Australia. The 
cells were cultured in F-12K nutrient mixture, Kaighn’s 
modification (Gibco, Life Technologies, The Netherlands), 
with added heat-inactivated 10% fetal bovine serum (FBS, 
Greiner Bio-one, The Netherlands) and 1% Penicillin/
Streptomycin (Gibco). CM2005.1 was created by S. 
Keijser, LUMC, Leiden, The Netherlands [48]. These cells 
were grown in RPMI 1640 Dutch modified media (Gibco) 
supplemented with 10% FBS (Greiner Bio-one), 1% 
GlutaMAX and 1% Penicillin/Streptomycin (Gibco). Our 
previous studies [49, 50] have shown that CRMM1 and 
CM2005.1 harbor a BRAF V600E mutation, and CRMM2 
contains an NRAS Q61L mutation. These mutations 
were confirmed at Erasmus University Medical Center, 
Rotterdam in May 2016 by next generation sequencing 
(NGS). Inactivating molecular changes in PTEN were 
tested by NGS as decribed before [51].
Cell line authentication
Short tandem repeat analysis was performed using 
the AmpFLSTR® Identifiler™ PCR Amplification 
Kit (Life Technologies, UK) based on the procedure 
recommended by The International Cell Line 
Authentication Committee (ICLAC) in Baseclear 
(Baseclear, Leiden, The Netherlands) in April, 2014, 
setting the standard for these three cell lines [50]. They 
were confirmed at Erasmus University Medical Center, 
Rotterdam in October 2014.
Immunoblotting
Cells were lysed in M-PER Mammalian Protein 
Extraction Reagent (78501, Thermo Scientific, OH, 
USA), supplemented with protease and phosphatase 
inhibitors (78415 and 78420, Thermo Scientific). Proteins 
(15-25 μg total protein lysates) were separated on Mini-
PROTEAN TGX Precast Gels (4-15%, Bio-Rad) using 
the Mini-PROTEAN Tetra system (Bio-Rad, Hercules, 
CA). Proteins were blotted onto polyvinylidene difluoride 
(PVDF) membranes (Immobilon-P, Millipore, Billerica, 
MA, USA) using the Trans-Blot Turbo System (Bio-
Rad). Subsequently, the membranes were incubated 
with the appropriate primary antibodies and IRdye-680 
or IRdye-800 dyes (LI-COR), and analyzed with the 
Odyssey Infrared Imaging System (LI-COR). Signal 
intensity was analyzed with Odyssey 3.0 software. 
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Alternatively, membranes were incubated with HRP-
conjugated secondary antibodies, and the bands were 
visualized by chemoluminescence (West Dura, Pierce 
Biotechnology, Rockford, IL, USA) and exposed to X-ray 
films (Fuji Super RX, Japan). Antibodies are listed below: 
BRAF (1:1000; ab33899, Abcam, Cambridge, UK); anti-
MAP kinase diphosphorylated ERK 1/2 (1:1000; M8159, 
Sigma-Aldrich); p44/42 MAPK (ERK1/2) (1:1000; 
4695, Cell Signaling Technology (CST), Leiden, The 
Netherlands); p-AKT (Ser473) (1:1000; 4060, CST); 
AKT (pan) (1:2000; 2920, CST); PARP (1:1000; 9542, 
CST); p-PRAS40 (Thr246) (1:1000; 2640, CST), PRAS40 
(1:1000; 2610, CST) and Vinculin (1:1000; V9131, 
Sigma-Aldrich).
Cell proliferation assay
Cells were seeded in triplicate in 96-well plates 
at a density of 2500 (CRMM1 and CRMM2) or 5000 
(CM2005.1) cells per well, in a total volume of 100 μl 
medium. The next day, the media were refreshed and 
cells were treated with drugs at various concentrations. 
Cell survival was determined 72 hours later by an In-cell 
western assay (Supplementary Figure S1): after removing 
the medium, the cells were fixed in 4% formaldehyde 
and incubated with DRAQ5, a far-red fluorescent DNA 
dye (1:8000, DR50050, Biostatus Ltd., UK) for 1 hour. 
After washing with 0.1% Tween-PBS (phosphate-
biffered saline) buffer, the plates were scanned with an 
Odyssey Infrared Imaging System (LI-COR, Leusden, The 
Netherlands). Odyssey 3.0 software was used to quantify 
the signal intensity. IC50 values were calculated on the 
basis of the growth inhibition curves and determined 
with CompuSyn software [32]. For synergy studies, drug 
effects were evaluated as “affected fraction” of treated 
versus untreated cells [52]. Dose-effect analyzes and 
Combination Index (CI) were calculated using CompuSyn. 
CI reflects the extent of synergy or antagonism for two 
drugs: CI<0.9, synergy; 0.9<CI<1.1, additive effect; 
CI>1.1, antagonism.
Flow cytometry
Cells were harvested, washed in PBS and fixed in 
ice-cold 70% ethanol and stored at -20°C. Subsequently, 
cells were washed with 2%FBS/PBS and suspended in 
2%FBS/PBS containing 50 μg/ml propidium iodide (PI) 
and 50 μg/ml RNase. Flow cytometry was performed 
in the BD LSR II system (BD Biosciences, Sparks, 
MD, USA) and the data were analyzed with FACSDiva 
software (BD).
Statistical analysis
Statistical analyses were performed with SPSS 
version 22.0 software (SPSS, Inc., Chicago, IL, USA). 
The Pearson chi-square test was used to compare the 
protein expression in vivo. Two-tailed P values equal to or 
below 0.05 were considered to be statistically significant. 
The plots of cell proliferation and cell cycle profiles were 
drawn with GraphPad Prism 5 software (La Jolla, CA, 
USA).
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